

8th Annual Meeting of the Lupus Academy

# Meeting Book


Warsaw, Poland

6–8th September 2019



**LupusAcademy**

Communicate. Educate. Treat.



# Welcome

## Dear Friends and Colleagues,

We are delighted to welcome you to the 8th Annual Meeting of The Lupus Academy<sup>†</sup> and hope you will find it a rich, engaging, informative and rewarding environment in which you can develop both your knowledge of managing lupus and exchange ideas with your peers.

The Lupus Academy is committed to continuing the development of high quality educational programmes, focused on providing insightful and clinically relevant content through both live meetings and eLearning environments. With this, we aim to support you as you strive to provide best-in-class patient care and improve patient outcomes in lupus.

This Annual Meeting, which has been certified for Continuing Medical Education (CME) credit, aims to provide latest insights into advances in global research and clinical practice in lupus and allied diseases. Delegate feedback from our previous annual meetings continues to guide us in selecting the topics and speakers you need to ensure translation of treatment advances into your clinical practice.

The scientific component of this programme, developed by our Steering Committee of 12 international experts in lupus, is designed to create a highly interactive forum through which we can all develop a logical approach to the management of lupus worldwide.

This meeting will give you the opportunity to meet like-minded clinicians and scientists and, through the sharing of clinical and scientific experience, develop your knowledge in this fast moving therapeutic area.

We sincerely hope that this meeting will provide you with new ideas for your clinical work, enriched enthusiasm for collaborative research, and fruitful discussions with your colleagues who care for patients with lupus.

We look forward to meeting and talking with you here in Warsaw.

With kind regards,

The Lupus Academy Steering Committee

**Professor Thomas Dörner**  
Lupus Academy co-Chair (2019)

**Professor Bernardo Pons-Estel**  
Lupus Academy co-Chair (2019)

**Professor Zahir Amoura**  
**Professor Bevra Hahn**  
**Professor Murray Urowitz**

**Professor Ricard Cervera**  
**Professor David Isenberg**  
**Professor Ronald van Vollenhoven**

**Professor Andrea Doria**  
**Professor Munther Khamashta**

**Professor Richard Furie**  
**Professor Sandra Navarra**

<sup>†</sup>The Lupus Academy is a long-term initiative dedicated to improving patient outcomes in SLE through an interactive educational forum dedicated to sharing best clinical practice through the dissemination and discussion of clinical and basic scientific research about SLE and allied diseases.



## Meeting Learning Objectives

The 8th Annual Meeting programme of the Lupus Academy will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both didactic lectures and shared clinical insights through case study workshops. At the end of the programme delegates should be able to:

- Understand the influence of cytokines in SLE pathogenesis and translational perspectives.
- Discuss current classification criteria for the effective management of SLE.
- Describe different lupus manifestations, their comorbidities and management of these in clinical practice (e.g. cardiovascular, kidney, CNS etc).
- Apply principles of the management of challenges like infection, nephritis, refractory lupus and pregnant patients with lupus.
- Discuss outcomes measurement in SLE including treat-to-target and low-disease activity states in principle and practice.
- Demonstrate understanding of targeting novel treatment pathways and their effect on clinical outcomes, including type 1 interferons, B cells, plasma cells and interleukin 12 and 23.
- Describe novel biomarkers used for monitoring lupus disease activity.
- Understand the best course of action in predicting and managing lupus flares and membranous lupus nephritis.

Abstracts of the presentations are published in the official journal of the 8th Annual Meeting:



The 8th Annual Meeting of the Lupus Academy is supported by independent educational grants from:  
GSK, Celgene and BMS

### Continuing Medical Education



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians. Siyemi Learning designates this live activity for a maximum of *14 AMA PRA category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Claiming Your CME Certificate

Participants will be able to claim their CME certificate online from the end of the meeting by completing a short feedback and reflection questionnaire online.

The CME credits offered are recognised across Europe and globally. Please check with your local authority to confirm its validity for your purposes.

### Disclosures

Financial disclosures of the speakers can be found with their biography in this book.

Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships to disclose.

Further information about Lupus Academy, partners and sponsors can be found on Page 22 of this book.

# Contents

Programme .....	6
Biographies.....	8
Notes.....	24



# Programme

Friday 6th September		
18:00–18:20	<b>Opening Address</b>	Bernardo Pons-Estel ( <i>Argentina</i> ) & Thomas Dörner ( <i>Germany</i> )
<b>Keynote Lecture</b>		<i>Moderator: Bevra Hahn (USA)</i>
18:20–19:00	Cytokines in SLE: Translational perspectives 2019	Lars Rönnblom ( <i>Sweden</i> )
<b>Debate: New developments in Basic Science and Clinical Research: Defining SLE</b>		<i>Moderator: Ricard Cervera (Spain)</i>
19:00–20:15	The matter of the debate (15 minutes)	Ricard Cervera ( <i>Spain</i> )
	Pro: We need better classification criteria for lupus (20 minutes + 10 minutes rebuttal)	Marta Mosca ( <i>Italy</i> )
	Con: We need a different approach: A molecular classification for connective tissue diseases (20 minutes + 10 minutes rebuttal)	Marta Alarcón-Riquelme ( <i>Spain</i> )
20:15	<b>Networking Event / Standing Buffet</b>	

Saturday 7th September		
<b>Plenary I: Lupus Manifestations and Comorbidities: How Have Our Strategies Improved?</b>		<i>Moderator: Sandra Navarra (Philippines)</i>
08:30–08:50	Cardiovascular outcomes and SLE in 2019	Murray Urowitz ( <i>Canada</i> )
08:50–09:10	Macrophage activation syndrome in SLE	Zahir Amoura ( <i>France</i> )
09:10–09:30	Evidence-based treatment of SLE comorbidities	George Bertias ( <i>Greece</i> )
09:30–09:50	Panel: Questions and Answers	
<b>Hot Topic Lecture</b>		<i>Moderator: Richard Furie (USA)</i>
09:50–10:30	APS in SLE patients: Best treatment practice	Munther Khamashta ( <i>UK</i> )
10:30–11:00	<b>Break</b>	
<b>Case Study Workshops (AM)</b>		
11:00–12:15	<i>Moderator/Facilitator: Murray Urowitz (Canada)</i> Management of refractory lupus: Place of biologics	 Bernardo Pons-Estel ( <i>Argentina</i> ) & Andrea Doria ( <i>Italy</i> )
11:00–12:15	<i>Moderator/Facilitator: Bevra Hahn (USA)</i> Management of difficult infections in SLE	 Zahir Amoura ( <i>France</i> ) & David Isenberg ( <i>UK</i> )
11:00–12:15	<i>Moderator/Facilitator: Munther Khamashta (UK)</i> Family planning and SLE: From conception through child-bearing	 Angela Tincani ( <i>Italy</i> ) & Ricard Cervera ( <i>Spain</i> )
11:00–12:15	<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i> Challenges in lupus nephritis	 Dimitrios Boumpas ( <i>Greece</i> ) & Richard Furie ( <i>USA</i> )
12:15–13:30	<b>Lunch</b>	

Case Study Workshops (PM)		
13:30–14:45	<i>Moderator/Facilitator: Murray Urowitz (Canada)</i> Management of refractory lupus: Place of biologics	 Bernardo Pons-Estel ( <i>Argentina</i> ) & Andrea Doria ( <i>Italy</i> )
13:30–14:45	<i>Moderator/Facilitator: Bevra Hahn (USA)</i> Management of difficult infections in SLE	 Zahir Amoura ( <i>France</i> ) & David Isenberg ( <i>UK</i> )
13:30–14:45	<i>Moderator/Facilitator: Munther Khamashta (UK)</i> Family planning and SLE: From conception through child-bearing	 Angela Tincani ( <i>Italy</i> ) & Ricard Cervera ( <i>Spain</i> )
13:30–14:45	<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i> Challenges in lupus nephritis	 Dimitrios Boumpas ( <i>Greece</i> ) & Richard Furie ( <i>USA</i> )
<b>14:45–15:10 Break</b>		
<b>State-of-the-art Lecture: Measuring Outcomes</b>		<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>
15:10–16:00	T2T, LLDAS and remission: Operational definitions meet reality?	Andrea Doria ( <i>Italy</i> )
<b>Plenary II: Novel Therapeutic Approaches to Improve Clinical Outcomes</b>		<i>Moderator: David Isenberg (UK)</i>
16:00–16:20	Targeting Type I interferons	Richard Furie ( <i>USA</i> )
16:20–16:40	Targeting B cells and plasma cells	David Isenberg ( <i>UK</i> )
16:40–17:00	Targeting interleukin 12/23	Ronald van Vollenhoven ( <i>Netherlands</i> )
17:00–17:20	Targeting novel intracellular pathways	Thomas Dörner ( <i>Germany</i> )
17:20–17:40	Panel: Questions and Answers	All Presenters
<b>17:40</b>	<b>Close</b>	David Isenberg ( <i>UK</i> )

Sunday 8th September		
<b>Keynote Lecture</b>		<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>
08:30–09:15	Novel biomarkers for monitoring lupus activity	Edward Vital ( <i>UK</i> )
<b>Hot Topic Lecture</b>		<i>Moderator: Ricard Cervera (Spain)</i>
09:15–10:00	Mind antibodies and CNS involvement in SLE: Differential diagnoses	Harald Prüß ( <i>Germany</i> )
<b>10:00–10:30 Break</b>		
<b>Roundtable: Treatment Challenges</b>		<i>Moderators: Munther Khamashta (UK) &amp; Lidia Rudnicka (Poland)</i>
10:30–11:00	When and how to escalate therapy in an impending flare	Bevra Hahn ( <i>USA</i> )
11:00–11:30	Management of refractory discoid lupus	Annegret Kuhn ( <i>Germany</i> )
11:30–12:00	Membranous nephropathy: How aggressive should I be?	Dimitrios Boumpas ( <i>Greece</i> )
12:00–12:20	Panel: Questions and Answers	All Presenters
<b>12:20–12:30</b>	<b>Close</b>	Thomas Dörner ( <i>Germany</i> ) & Bernardo Pons-Estel ( <i>Argentina</i> )

## Biographies



### Financial Disclosures

**Grants/Research:** Bayer; Eli Lilly; IRIS; Sanofi; Servier; UCB

### Professor Marta E. Alarcón-Riquelme, MD, PhD

Center for Genomics and Oncological Research, Granada, Spain

Institute for Environmental Medicine, Karolinska Institute, Stockholm, Sweden

Marta E. Alarcon-Riquelme is Head of the Medical Genomics Area at the Center for Genomics and Oncological Research (GENYO), Granada, Spain and Visiting Professor at the Karolinska Institute, Stockholm, Sweden. Professor Alarcon-Riquelme studied Medicine in Mexico, before moving to Sweden in 1987 where she was awarded her PhD in Immunology from Stockholm University in 1994. After her PhD she began forming research collaborations, which allowed her to build banks of samples for genetic studies, families and case-control sets. These efforts, and financing from the European 4th Framework Programme, allowed her to publish the identification of the first gene resulting from genetic linkage analyses of systemic lupus erythematosus (SLE) families, PDCD1, and the very first example of how to analyse a genetic polymorphism with impact on transcription factor binding and gene expression. In several subsequent studies, Professor Alarcon-Riquelme identified BANK1 and developed understanding of the mechanisms through which genetic polymorphisms modulate gene function for IRF5, CD226 and fine mappings of various genes published in top journals. Following these research activities, Professor Alarcon-Riquelme was invited to become a member of the International Lupus Genetics Consortium.

Professor Alarcon-Riquelme has been Editorial Advisor for the journal *Genes & Immunity* and has served as Advisory Editor of *Arthritis & Rheumatism* and has been an invited speaker to over 60 meetings and congresses since 1996. She has been a grant evaluator for the Swedish Research Council (presiding in 2006, 2008 and 2009), Wellcome Trust (2001, 2004), Arthritis Research Campaign (2004, 2007), European Young Investigator Awards for Sweden (2007), and Academy of Finland (2011–2013), among others.

Professor Alarcon-Riquelme has dedicated her career to the understanding of the autoimmune disease SLE, focusing on the identification of susceptibility genes and how these impact on cell function. Since 1997, she has trained Masters Students, PhD students and postdoctoral graduates and, since 2009, coordinated the European Research Network BIOLUPUS with members from 10 European countries funded through the European Science Foundation (2009–2014); this network consolidated clinical information from all European SLE patients and centralises data and samples for genetic analyses. Professor Alarcon-Riquelme also coordinates two large multicentre collaborations in Latin America on lupus (GENLES) and rheumatoid arthritis (GENAR) involving 60 clinical centres. Most recently, she has received important support from the Innovative Medicines Initiative-Joint undertaking of the European Union to study the molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases, a project she coordinates that includes 28 partners among which there are five major pharmaceutical companies. She has also received support from the Alliance for Lupus Research to research the Influence of BANK1 in the *In Vivo* Development of Lupus and support from the Consejería de Economía, Innovación y Ciencia (Spain) to help characterise Spanish SLE patients for genetic studies.



**Professor Zahir Amoura, MD, MSc**

French National Reference Centre for SLE and APS, Pitie-Salpetrière Hospital, Paris, France

*Professor Amoura is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

**Financial Disclosures**

**Grants/Research:** Amgen; GSK

**Consultant/Advisor:**

AstraZeneca; GSK

**Speaker's Bureau:**

AstraZeneca; GSK

Zahir Amoura is Professor of Internal Medicine and Head of the Department of Internal Medicine at the French National Reference Centre for Systemic Lupus Erythematosus at Pitie-Salpetrière Hospital. Professor Amoura completed his Paris Hospital Medical Internship in 1988, and obtained a Master's degree in Immunopharmacology in 1989. He was subsequently awarded his MD (silver medal) in 1993 and his qualifying certification in internal medicine in 1994. Professor Amoura joined the Department of Internal Medicine at Pitie-Salpetrière Hospital in 1995 as a Senior Lecturer and Senior Practitioner. He has been Professor of Internal Medicine there since 2003, and in 2009 became Head of the Department of Internal Medicine in the same institution.

In the last 15 years, he has published over 370 peer-reviewed papers, of which 170 focused on the immunopathological features of lupus.



**Professor George Bertsias, MD, PhD**

University of Crete Medical School, Greece

**Financial Disclosures**

**Grants/Research:** GSK

**Consultant/Advisor:**

AbbVie; GSK; Novartis;

Pfizer; UCB

George Bertsias graduated from the University of Crete School of Medicine (UoCSM) in 2002. After his internship, he pursued graduate studies and received his MSc degree in 2006 and PhD in immunology/autoimmunity in 2009. During the same period, he was also engaged in and co-supervised high-throughput gene expression studies, which yielded gene pathways implicated in autoimmune responses. He has performed post-doctoral research in the laboratory of Dr Daniel Kastner at the National Institute of Human Genome Research Institute, National Institutes of Health (NIH/NHGRI). Professor Bertsias is board certified in Internal Medicine and in Rheumatology.

Since 2008, Professor Bertsias has developed scientific interest in systemic autoimmunity and Systemic Lupus Erythematosus (SLE) and has been an active member of the EULAR study group on SLE, where he has coordinated the preparation of a number of clinical recommendations for the diagnosis and treatment of patients with SLE, including lupus nephritis, neuropsychiatric lupus and management of pregnancy in women with SLE. He is a EULAR-accredited clinical methodologist.

In 2014, he was appointed Lecturer in Rheumatology-Clinical Immunology and Principal Investigator at the Laboratory of Autoimmunity and Inflammation, UoCSM. His research focuses on immune regulation by costimulatory receptors, inflammatory cytokines and cellular metabolic pathways using SLE as a disease-model and by applying high-throughput technologies in patient tissues. In addition, Professor Bertsias has organized and runs a dedicated Connective Tissue Diseases (CTDs) / SLE clinic that serves as referral center for the island of Crete and Southern Aegean region. He also manages the Cretan Lupus Registry, which has registered more than 700 SLE patients with complete sociodemographic and clinical characteristics. Professor Bertsias has established collaborations with other research groups in Europe and the US and has actively participated and supervised several projects related to diagnostic and therapeutic aspects of SLE. In July 2016, he was promoted to Assistant Professor at UoCSM. He has published more than 100 peer-reviewed papers (PubMed) and several textbook chapters pertinent to SLE.

## Biographies



**Dimitrios T Boumpas, MD, FACP**  
National and Kapodistrian University of Athens, Greece

### Financial Disclosures

None

Dimitrios Boumpas, graduated from the Medical School of the University of Ioannina in 1983. Following a fellowship in Molecular Immunology at National Institutes of Health (NIH), Bethesda MD, he trained in Internal Medicine at Georgetown University, Washington DC and in Rheumatology-Clinical Immunology at ARB, NIAMS, NIH. Upon the completion of his training, he was appointed an Investigator at ARB, NIAMS, NIH where he served as Deputy and Acting Clinical Director. In 1999 he repatriated to the University of Crete to lead the Departments of Rheumatology, Clinical immunology and Allergy, and Internal Medicine. While in Crete, Professor Boumpas Directed the

Graduate Program on the Molecular Basis of Human Diseases. In 2012 he joined the Medical School, University of Athens where he currently serves as the Chairman of the Fourth Department of Medicine at the "Attikon" University Hospital. He is also an Affiliated Member of the Institute for Biomedical Research of the Academy of Athens. Professor Boumpas primary clinical and research interests are in the areas of human autoimmunity with emphasis on systemic lupus erythematosus and inflammatory arthritis. His work on the treatment of lupus nephritis has shaped immunosuppressive therapy internationally.



**Professor Ricard Cervera, MD, PhD, FRCP**  
Hospital Clinic, Barcelona, Catalonia, Spain

*Professor Cervera is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

### Financial Disclosures

AstraZeneca; Celgene;  
GSK; Pfizer, UCB

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clinic, Barcelona. He is also leader of the Research Team on Systemic Autoimmune Diseases at the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Professor at the University of Barcelona where he coordinates the Masters Course on Autoimmune Diseases and serves as Vice-Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. He qualified in medicine in 1983 from the University of Barcelona and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Professor Cervera is an Associate Editor of the journal *Lupus Science & Medicine* and is on the Editorial Boards of 20 medical journals. He is Founder and Member of the Board of the European Lupus Society and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the

Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly SLE and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 300 invited lectures and published more than 800 scientific papers (H-Index, 79), including original articles in the *New England Journal of Medicine*, *The Lancet*, *Annals of Rheumatic Diseases*, *Arthritis & Rheumatism*, *American Journal of Medicine* and *Medicine (Baltimore)*. He is co-Editor of 25 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.



**Professor Andrea Doria, MD**  
University of Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit and Unit of Connective Tissue Disease and Rare Rheumatic Diseases, Department of Medicine, University of Padua, Italy.

*Professor Doria is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

**Financial Disclosures**

**Consultant/Advisor:**

Biogen; Lilly; Pfizer; Roche

**Speaker's Bureau:**

Biogen; Lilly; Pfizer; Roche

Professor Doria received his medical degree and qualification in Rheumatology from the University of Padua. He was Council member of the Italian College of Rheumatology (CRO) between 1999 and 2005 and a Council member of the Italian Society of Rheumatology (SIR) from 2007 to 2010 and from 2013 to present. He is also a member of American College of Rheumatology (ACR).

Professor Doria has organised over ten international conferences on autoimmunity and was involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations: (1) EULAR recommendations for the management of systemic lupus erythematosus (SLE)—Assessment of the SLE patient (2008–2009); (2) EULAR recommendations for the management of SLE Part II—Neuropsychiatric disease (2008–2009); (3) Joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012). Professor Doria is a member of the Lupus Academy Steering Committee and co-Chaired the 4th Annual Meeting held in Rome 27th February to 1st March 2015. He was the chair of the 10th European Lupus Meeting, held in Venice (Italy) 5–8th October 2016.

Professor Doria is on the Editorial Boards of several rheumatology and immunology journals, including *Lupus*, *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews*, *Journal of Autoimmunity*, *Experimental Biology and Medicine*, *Rheumatology Reports*, *Journal Autoimmunity Highlights* and *Reumatismo* (the official journal of Italian Society of Rheumatology).

He has authored over 300 ISI publications on SLE and other connective tissue diseases. These include clinical studies describing new manifestations or subgroups of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions, as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens. In addition, he has authored and co-authored three books, over 90 book chapters and conference proceedings, and over 700 abstracts for national and international conferences.

Professor Doria has long-standing experience of the clinical management of patients with connective tissue diseases. The unit in which he works is a tertiary referral rheumatology centre within Italy, for the diagnosis and management of patients affected with systemic connective diseases. In addition, he has expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases. Professor Doria has also trained over 30 students in Rheumatology.

## Biographies



**Professor Thomas Dörner, MD**  
Charite University Hospitals Berlin, Germany

*Professor Dörner is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

### Financial Disclosures

None

Thomas Dörner is a board certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charite University Hospitals, Berlin, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charite University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received a number of international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including *Arthritis & Rheumatism*, *Arthritis Research & Therapy*, *Annals of the Rheumatic Diseases*, *Global Arthritis Research Network (GARN)*, *Current Reviews in Rheumatology*, *the Brazilian Journal of Rheumatology*, *the European Journal of Immunology*, *Lupus Science & Medicine*, and *Rheumatology Reviews*.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood *versus* tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.



**Professor Richard Furie, MD**  
Hofstra Northwell School of Medicine, New York, USA

*Professor Furie is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

### Financial Disclosures

Grants/Research:  
AstraZeneca/Medimmune;  
Biogen; Janssen;  
Genentech

### Consultant/Advisor:

AstraZeneca/Medimmune;  
Biogen; Janssen;  
Genentech

Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a Rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, Northwell Health System's clinical research program in musculoskeletal disease. He also directs the Hospital's SLE and Autoimmune Disease Treatment Center, which has become internationally recognised for its role in the development of new therapies for systemic lupus erythematosus (SLE).

Regarded as one of the senior Rheumatologists in the New York metropolitan area, Professor Furie has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For 20 years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.



**Professor Bevra Hahn, MD**  
University of California, Los Angeles, USA

*Professor Hahn is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*


**Financial Disclosures**

**Grants/Research:** BMS  
**Consultant/Advisor:**  
Janssen

Bevra Hahn is Distinguished Professor of Medicine (Emeritus, recalled for part time work) in the Division of Rheumatology at the University of California, Los Angeles (UCLA). She received her medical degree and Rheumatology training at Johns Hopkins University School of Medicine in Baltimore, Maryland. She was Chief of Rheumatology at UCLA for 30 years.

Professor Hahn has published research in clinical investigations and basic studies of immune tolerance (including the invention of a tolerizing peptide) and T-cell biology as they apply to systemic lupus erythematosus (SLE). For these works she and her colleagues have received

several awards, including the Carol-Nachman International Award for Rheumatology Research, awards from the British Society for Rheumatology and the Dutch Society for Rheumatology, the James Klinenberg Medal of the US Arthritis Foundation, an award from the Canadian Rheumatism Society, and the Gold Medal of the American College of Rheumatology (ACR). Professor Hahn was President of the ACR (1999–2000). She is co Editor, with Daniel Wallace, of the ‘Dubois’ Lupus Erythematosus textbook and is first author of the ACR guidelines for the management of lupus nephritis. She continues to work in clinical research devoted to the study of SLE.



**Professor David Isenberg, MD, FRCP, FAMS**  
University College London, UK

*Professor Isenberg is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

**Financial Disclosures**

None

David Isenberg is the Arthritis Research UK Diamond Jubilee Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew’s Hospital, London, in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the arc Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

Professor Isenberg is on the Editorial Boards of five journals, including the *Journal of Rheumatology*. He is Chair of the British Isles Lupus Assessment Group and Lupus UK’s Research Committee and was Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at Arthritis Research UK and currently sits on the Executive Board.

He is past-President of the British Society for Rheumatology (2004–2006) and he chaired the Society’s Biologics Register Committee for 5 years (2006–2011). Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 550 original articles, 275 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg’s principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is autoimmune rheumatic diseases, notably systemic lupus erythematosus, Sjogren’s syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology.

## Biographies



**Professor Munther Khamashta, MD, PhD, FRCP**  
London Bridge Hospital, London, UK

*Professor Khamashta is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

### Financial Disclosures

None

Munther Khamashta is a Rheumatologist at London Bridge Hospital, London, UK. He studied medicine in Barcelona and internal medicine in Madrid, Spain, where he developed an interest in connective tissue diseases and received his PhD. He was awarded the MRCP in 1999 and FRCP in 2002. He joined the Lupus Unit at St. Thomas' Hospital in London 30 years ago and has been instrumental in developing it into an internationally recognised tertiary centre receiving referrals from all over the UK. He is currently on sabbatical setting up lupus services at Dubai Hospital, United Arab Emirates.

Professor Khamashta has served on the Editorial Boards of many journals, including *Clinical & Experimental Rheumatology*, *Lupus*, and *Current Rheumatology Reviews*. He is a member of several professional societies, including the International

Society of Internal Medicine, the American College of Rheumatology and the Spanish Society of Rheumatology. He is a member of the Steering Committee of the International Board on the Study of Antiphospholipid Antibodies and of the Steering Committee of the International Advisory Board for Systemic Lupus Erythematosus. He is a founding member of the Lupus Academy and APS-ACTION. He has received several international awards for his work, including the European League Against Rheumatism and International League Against Rheumatism prizes.

Professor Khamashta has a strong research interest in lupus and connective tissue diseases, with a special interest in pregnancy and antiphospholipid syndrome. He has published extensively in lupus, Hughes syndrome and related areas, with more than 700 original papers.



**Professor Annegret Kuhn, MD, MBA**  
University Hospital Münster, Germany

Photo: D. Witte / Weltendorff

### Financial Disclosures

None

Annegret Kuhn is Professor of Dermatology and Venerology and Head of the Executive Department of the Management Board at University Hospital Münster, Germany.

Professor Kuhn acquired her medical degree and her Doctor of Medicine at the University of Düsseldorf, Germany, where she also received her German Board Certification for Dermatology and Venerology and her Qualification as University Lecturer. She has also worked in scientific institutions, such as the Max-Planck-Institute for Molecular Biomedicine, Münster, and the German Cancer Research Center, Heidelberg, Germany. Professor Kuhn has also completed the MBA Health Care Management Program at the University of Bayreuth, Germany. Professor Kuhn was Head of the Interdisciplinary Center for Clinical Trials at the University Medical Center, Mainz, Germany from 2014 to 2017.

Professor Kuhn's major clinical and scientific interest is translational immunology, particularly the pathogenesis, diagnosis, and treatment of cutaneous lupus erythematosus. She has also acquired extensive knowledge and long-term experience in academic care of in-patients and out-patients with autoimmune diseases. Professor Kuhn has chaired national and international guideline subcommittees and the European Society of Cutaneous Lupus Erythematosus (EUSCLE). She has published widely in high impact journals, including more than 200 original and review articles.



**Professor Marta Mosca, MD, PhD**  
 University of Pisa, Italy

**Financial Disclosures**

None

Marta Mosca is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. She is also Head of the Fellowship Training Program in Rheumatology of the University of Pisa and member of the faculty of the PhD Program in Genetics, Oncology and Clinical Medicine of the Consortium among the Universities of Pisa, Florence and Siena.

Professor Mosca received her medical degree, qualification in Rheumatology and PhD from the University of Pisa. Her clinical activity covers systemic lupus erythematosus (SLE) as well as other rare and complex connective tissue diseases and rheumatic diseases. She is also responsible for the Lupus clinic and, since 2000, the pregnancy clinic.

Since 2003, Professor Mosca has organized the “EULAR endorsed course in Systemic Lupus Erythematosus”, which is held every 2 years in Pisa as a residential course dedicated to the discussion of the many aspects of the SLE. She has also contributed to the development of EULAR recommendations, including women’s health and the management of family planning,

assisted reproduction, pregnancy and menopause in patients with SLE and/or antiphospholipid syndrome, management of antiphospholipid syndrome in adults, and the 2019 update of the management of SLE. Professor Mosca also coordinated the development of recommendations for monitoring SLE patients in clinical practice and in observational studies.

Since December 2016, Professor Mosca has been the Coordinator of the European Reference Network on “Rare and Hereditary Connective and Musculoskeletal Diseases” (RECONNET) promoted by the European Commission. She is also the coordinator of the European Commission Program INTEGRATE, which aims to integrate physician and the patient views on the management of SLE. She has been a member of the the EULAR-ACR Steering Committee for the development of classification criteria for SLE and serves as a member of the Scientific Advisory Board of LUPUS EUROPE, the European Association of SLE patients.

Professor Mosca has authored over 200 ISI publications on SLE and other connective tissue diseases.



**Professor Sandra Navarra, MD, FPCP, FPRA**  
 University of Santo Tomas, Manila, Philippines

*Professor Navarra is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

**Financial Disclosures**

None

Professor Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas, Manila, Philippines. She served as Secretary-General, Head of the Education Committee, chaired the special interest group on systemic lupus erythematosus of the Asia Pacific League of Associations for Rheumatology (APLAR), and was President of the Philippine Rheumatology Association. She founded the Lupus Foundation of the Philippines where she has served as Medical Adviser. Currently President and CEO of the Rheumatology Educational Trust Foundation Inc. (RETFI), she is the prime mover of the Lupus Inspired Advocacy (LUISA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) movement for lay education and medical assistance programmes. Professor Navarra is a founding member of the Lupus Academy Steering Committee and a founding and executive board

member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

Professor Navarra is an experienced clinical trials investigator and has published widely in the field of lupus and other rheumatic diseases. She is a well-known lecturer in a broad range of topics in rheumatology and has received several university and national awards for contributions to education and research. She has organised several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), the first Asian Lupus Summit (November 2012), the Asian Lupus Summit by the Lupus Academy (March 2014), the Lupus Nephritis Forum (July 2015), the Lupus Academy Roadshow Meetings (May 2016 and November 2017) and the “Lupus for the Internist” postgraduate courses (April 2018, May 2018), all held in the Philippines.

## Biographies



### **Professor Bernardo Pons-Estel, MD**

Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina

*Professor Pons-Estel is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

#### **Financial Disclosures**

None

Bernardo Pons-Estel is head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR), and the Cardiovascular Institute of Rosario (ICR), Argentina. He received his medical degree from the National University of Rosario and went on to train in rheumatology, first in Argentina (Rosario) and thereafter the USA, where he was a fellow at New York University (Bellevue Hospital and the Irvington House Institute, New York) and at the University of Missouri Cancer Research Center, Columbia.

Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), the Genomic Study of Latin-American Patients with SLE (GLA-GENLES) and the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO).

He is past-President of the Argentinean Rheumatology Society (2011–2013). In 2013, he chaired the 10th International Congress on SLE, which took place under GLADEL sponsorship in Buenos Aires, Argentina and in 2018 he chaired the Pan-American League of Rheumatology Associations (PANLAR) Congress in Buenos Aires.

Professor Pons-Estel is a council member of the Science and Educational Committee of the Pan-American League of Association for Rheumatology (PANLAR). He is also an active member of the Systemic Lupus International Collaborating Clinics (SLICC), member of the Lupus Academy Steering Committee and an International Member of the ACR. Recently, a collaboration between GLADEL and PANLAR materialised, the aim being the development of guidelines for the management of SLE patients from the Latin American subcontinent; Bernardo is an integral part of this collaboration.



### **Harald Prüss, MD**

German Center for Neurodegenerative Diseases Berlin and Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, Germany

#### **Financial Disclosures**

None

Harald Prüss is group leader for Autoimmune Encephalopathies at the German Center for Neurodegenerative Diseases (DZNE) Berlin, Consultant Neurologist at the Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, and Head of the autoimmune encephalitis center and outpatient memory clinic at Charité Berlin, Germany.

Dr Prüss received his medical degree and qualification in Neurology from the Charité – Universitätsmedizin Berlin, as well as the habilitation (*venia legendi*) in Experimental Neurology and Neurology. His postdoctoral training was undertaken in Berlin and at the Department of Immunology at Harvard Medical School, Boston. His group is active in the field of cellular and molecular neuroscience, in particular in autoimmune contribution to neurological disorders, animal models of antibody-mediated CNS diseases, synaptic changes caused by pathogenic auto-antibodies and nervous system-immune system 'crosstalk' in acute and chronic brain diseases.

Dr Prüss' studies on the first monoclonal human autoantibodies targeting NMDA and further brain receptors were a paradigm shift as they proved the direct pathogenicity of these antibodies and at the same time provide the rationale to treat such patients with often aggressive immunotherapy. His work is published in the top journals in the field, including *Nature Neuroscience*, *Annals of Neurology*, *JAMA Neurology*, *Brain*, *Neurology* and *Biological Psychiatry*.



**Professor Lars Rönnblom, MD, PhD**  
Uppsala University, Sweden

Lars Rönnblom is Professor of Rheumatology and Head of the Department of Medical Sciences at Uppsala University, Sweden.

Professor Rönnblom received his PhD in Immunology in 1983 and board certification in internal medicine in 1989. He has been a board certified Rheumatologist since 1994 and was appointed Professor of Rheumatology at Uppsala University in 2006. He is Senior Consultant in Rheumatology and responsible for the lupus clinic at Uppsala University Hospital. He is also group leader for the Rheumatology section at the Department of Medical Sciences and coordinates the Swedish systemic lupus erythematosus (SLE) network.

Lars Rönnblom has received a number of awards for his research, including the Scandinavian Research Foundation/Scandinavian Journal of Rheumatology's award for research in rheumatology, the Wyeth Prize for Clinical Research in Rheumatology and the Thuréus prize from The Royal Society of Science. He has served as a member of a number of Editorial Boards and is currently one of the Associate Editors at *Lupus Science & Medicine*.

Professor Rönnblom have been working on the aetiopathogenesis of SLE for more than 30 years and his main focus is the role of the Type I Interferon system in the development of SLE and other systemic autoimmune diseases. He first described the mechanisms behind the activation of plasmacytoid dendritic cells in SLE. Professor Rönnblom's other areas of interest include the genetic background to disease susceptibility and clinical manifestations of SLE. His group have made seminal contributions to the identification of a number of risk genes of importance in SLE and clarified the functional consequences of several disease-associated gene variants.

**Financial Disclosures**

**Grants/Research:**

AstraZeneca

**Consultant/Advisor:**

Biogen

## Biographies



### Professor Angela Tincani, MD

University of Brescia, Italy

#### Financial Disclosures

**Grants/Research:** AbbVie; BMS; Pfizer; UCB

#### Speaker's Bureau:

Janssen; Pfizer; Roche; UCB

Angela Tincani is Professor of Rheumatology at the Department of Clinical and Experimental Science, University of Brescia, and Head of the Rheumatology and Clinical Immunology Unit at the "ASST-Spedali Civili di Brescia", Italy.

Professor Tincani received her medical degree and qualification in Clinical Immunology and Rheumatology from the University of Milan. She was a Council Member of the Italian Society of Rheumatology (SIR) from 2015 to 2018; Member of the EULAR Scientific Committee (2017–2019); and invited by the American College of Rheumatology to serve as an abstract category co-Chair of the "Reproductive issues in Rheumatic disorders"(2017–2019) category.

Professor Tincani has been committee member or chair of many international conferences on systemic lupus erythematosus (SLE), antiphospholipid antibodies, autoimmunity, and pregnancy in rheumatic diseases. She was involved in the EULAR task forces as an "expert" for the development of recommendation: (1) "EULAR Recommendations for Management of SLE and Clinical End-Points in Lupus Trials", (2) "Physical Examination and its Relationship to Functional Anatomy in Rheumatology", (3) "Development of Recommendations for Monitoring SLE Patients in Clinical Practice and in Observational Studies", and (4) "Points to consider for use of anti-rheumatic drugs before pregnancy and during pregnancy and lactation". In addition, she proposed and conducted, as co-Chair, the EULAR task forces on: (1) "Development and validation of a new patient reported outcome questionnaire to estimate vitamin D status and its correlation with quality of life, disease activity and disability in rheumatoid arthritis patients in Europe", (2) "Recommendations for the management of family planning, assisted reproduction, gestation, delivery and menopause in patients with systemic lupus erythematosus and Antiphospholipid Syndrome", (3) "Recommendations for the management of adult Antiphospholipid Syndrome". Dr Tincani will chair the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases which will be held in Stresa, Italy, 1–3 October 2020.

Professor Tincani is on the Editorial Boards of several journals including: *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews* and *Reumatismo* (the official journal of Italian Society of Rheumatology).

She has authored more than 300 publications on the management of patients with systemic autoimmune diseases, regarding both diagnosis (including validation and use of novel biomarkers) and treatment (including new drugs trials and clinical) of: SLE, antiphospholipid syndrome, systemic sclerosis, systemic vasculitis, inflammatory myositis and inflammatory arthritis. Several publications focuses on reproductive related issues such as: (1) management of patients with rheumatic diseases during pregnancy; (2) use of anti-rheumatic drugs during pregnancy and lactation; and (3) evaluation of different autoimmune diseases and autoantibodies as risk factors for poor gestational outcomes.

Professor Tincani has broadly recognized experience in the clinical management of patients with autoimmune rheumatic diseases, and Rheumatology and Clinical Immunology unit of Brescia, where she works, is a tertiary referral center for SLE, antiphospholipid syndrome and systemic sclerosis. In addition, since 1990, Professor Tincani has been responsible for the multidisciplinary Pregnancy Clinic in Rheumatic Diseases, in close collaboration with Obstetrics and Gynecology Department and Neonatal Intensive Care Unit of the ASST-Spedali Civili/ University of Brescia.

As Professor of Rheumatology and Director of the Rheumatology Specialization School of Brescia University, Professor Tincani trained many students and fellows.



**Professor Murray Urowitz, MD**  
University of Toronto, Canada

Murray Urowitz is Professor of Medicine at the University of Toronto and Director of the Centre for Prognosis Studies in the Rheumatic Diseases and the Lupus Clinic at the Toronto Western Hospital.

Professor Urowitz has published over 400 peer-reviewed papers and 44 book chapters. He has supervised the training of over 140 fellows in rheumatology especially in systemic lupus erythematosus.

*Professor Urowitz is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

**Financial Disclosures**

None

Professor Urowitz was a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and currently directs the SLICC Registry for Atherosclerosis. In 1995 he was the recipient of the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he was recipient of the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He was the recipient of the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May 2019 was the recipient of the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact.

# Biographies



## Professor Ronald van Vollenhoven, MD, PhD

Amsterdam University Medical Centers, and Amsterdam Rheumatology & Immunology Center

*Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 8th Annual Meeting programme and materials.*

### Financial Disclosures

**Grants/Research:** AbbVie; BMS; GSK; Pfizer; UCB

### Consultant/Advisor:

AbbVie; AstraZeneca; Biogen; Biotest; BMS; Celgene; Gilead; GSK; Janssen; Lilly; Novartis; Pfizer; Servier; UCB

### Speaker's Bureau:

AbbVie; Lilly; Pfizer; UCB

Professor Ronald F. van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and immunology Center ARC in Amsterdam, the Netherlands.

He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by residency (specialty training) in Internal Medicine at the State University of New York at Stony Brook, and a fellowship in Rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 he moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

In January 2016 Professor Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the Amsterdam Rheumatology and Immunology Center ARC, and Chair of the Rheumatology Research Council at Reade in Amsterdam, all located in Amsterdam, The Netherlands.

Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database) for this purpose, which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 300 original papers (H-index: 65), book chapters and reviews, and is associate-editor of Dubois' *Lupus Erythematosus* (Elsevier, 2014), editor of the textbook *Clinical Therapy Research in the Inflammatory Diseases* (World Scientific Press, 2015), author of the monograph *Biological Therapy of Rheumatoid Arthritis* (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the *Handbook of Systemic Lupus Erythematosus* (Springer, 2017). In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatological societies. He is the Editor-in-Chief of *Lupus Science & Medicine*, Member-elect of the EULAR Executive, past-Chair of the Swedish Rheumatology Society Professors' Council, co-founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives. Professor van Vollenhoven is married and has two children aged 23 and 19. Outside his professional life he is an avid classical pianist.



**Associate Professor Edward Vital, MD, PhD**  
Leeds University, UK

Ed Vital is an Associate Professor and Rheumatologist at the University of Leeds and Leeds Teaching Hospitals NHS Trust in the UK. He leads the Leeds lupus research group and tertiary referral centre.

**Financial Disclosures**

**Consultant/Advisor:**

AstraZeneca; Genentech;  
GSK

**Speaker's Bureau:** GSK

Dr Vital received his medical degree from the University of Manchester and trained in rheumatology in Leeds. His PhD from the University of Leeds focussed on B-cell depletion therapy, including determinants of response across multiple rheumatic diseases. Since then he has worked extensively in clinical translational research in lupus. In the area of B-cell depletion therapy he demonstrated mechanisms of response and relapse, and used this to develop novel treatment strategies. His work on Type I Interferons improved the evaluation of interferon status with a series of biomarker studies, including prediction of onset of systemic lupus erythematosus (SLE) and demonstration of mechanisms of interferon

dysregulation. In skin disease he showed that some subtypes were resistant to B-cell therapies and completed clinical trials of alternative novel therapies. In musculoskeletal imaging he used imaging to explain symptoms and develop new outcome measures. His current interest is particularly in patients at risk of SLE, studying mechanisms and predictors of progression.

Dr Vital is the UK representative to the EULAR Standing Committee for Investigative Rheumatology, EULAR study group for SLE, and a member of the Versus Arthritis Research Advisory Group. He is Convenor of a EULAR taskforce for Interferon Biomarkers. Since 2019 has been Chair of the British Isles Lupus Activity Group. In 2019 he was awarded the British Society for Rheumatology Michael Mason prize and the Medical Research Foundation Emerging Leaders prize for his research.



# About the Lupus Academy

## Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

## Meeting Organisation

The 8th Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Thomas Dörner (Germany) and Professor Bernardo Pons-Estel (Argentina), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

## Other Educational Activities

The Lupus Academy runs an Annual Meeting and several regional Roadshow Meetings each year. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy is also developing a series of eLearning activities to support its educational goals.

From 2019 Lupus Academy is proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR).

More information about all Lupus Academy educational activities can be found at [lupus-academy.org](http://lupus-academy.org).

## Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in The Netherlands, RSIN 851342097.  
Lupus Academy Foundation  
Maasdijk 409  
4264 AS Veen  
The Netherlands



The Lupus Academy is the proud provider of the eLearning Course on SLE for the European League Against Rheumatism



## Supporters

The Lupus Academy education programme is supported through financial and in-kind support.

Independent educational grants from:

GSK, Celgene and BMS

Sponsorship of the 8th Annual Meeting:

**Silver Sponsor**

Boehringer Ingelheim, Janssen, Roche

**Bronze Sponsor**

AstraZeneca

**Academy Partner**

Biogen, Boston Pharmaceuticals, Servier

The official journal of the 8th Annual Meeting:



The Polish Dermatological Society is an Honorary Patron of the 8th Annual Meeting.



Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or in-kind, and where used, clearly identified.









































